c W e thank Alffenaar and colleagues on their very insightful comments regarding the new breakpoints for multidrugresistant tuberculosis (MDR TB) (1). We agree that the impact of the definition goes beyond statistical increases in the prevalence of MDR TB and has a direct impact on who should be treated with first-line regimens. Revision of breakpoints implies changing the regimens on which patients are started. Patients may be started on less effective second-line drugs with more toxicity. However, a preferred solution is exactly what Alffenaar and colleagues suggest, i.e., to use pharmacokinetics/ pharmacodynamics (PK/PD) to define the drug doses necessary to overcome the high MICs.
